Diabetes

Three physicians presented results of CANVAS and CANVAS-R, as well as other studies, and invited questions about the use of canagliflozin in primary care.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included the end of the latest attempt to repeal the Affordable Care Act; a call to better include the patient's voice in cancer quality metrics; and an argument for caution regarding the newly approved CAR T-cell therapy, Kymriah.

Novo Nordisk announced that the FDA has approved its insulin aspart injection Fiasp, which can rapidly improve glycemic control at mealtimes for patients with type 1 and type 2 diabetes.

A continuous glucose monitor (CGM) device made in the United States is finally approved for use here after patients in 40 other countries already have access.

HHS has challenged mobile app developers and other technology innovators to create an intervention to promote nutrition, health, and fitness among low-income children and families.

The FDA has announced the 9 companies that will participate in a pilot precertification program to speed the approval of digital health software.

The pilot program is the latest venture among stakeholders in diabetes care to look for ways to deploy patient data to improve outcomes and hold down costs.

The move to give entrepreneurs access to patient-approved continuous glucose monitoring data fits with the company's prediction that insulin pumps will become a thing of the past, and most of the heavy lifting of delivery will be done by a smartphone.

With 35% of Americans having prediabetes, prevention is clearly a priority, but many strategies have not bee translated into clinical practice because there is no system for reimbursement yet, explained Paul Chew, MD, chief medical officer of Omada Health

Outcomes-based pricing arrangements for pharmaceuticals are increasingly popular. In this piece, we discuss the impact of the outcomes-based pricing arrangements proposed by Amgen on the pricing of PCSK9 inhibitor therapy, and we provide recommendations for payers on the design of outcomes-based contracts.

UnitedHealthcare has not released numbers on how many patients are affected by its exclusivity deal with Medtronic. While the initial press stories criticizing the transaction have died down, a JDRF initiative calls on insurers to preserve patient choice.

Studies presented at the American Diabetes Association Scientific Sessions showed that patients being treated with the ITCA 650 were less likely to need to take additional therapy to control their diabetes.

The latest version of the free app offers patients a simple color-coding system to track their blood sugar status, as well as an easy way to share data with their physicians and perhaps their health plan.

Patients using secure online messaging to communicate with their healthcare providers about their type 2 diabetes (T2D) demonstrated improved clinical outcomes, according to a new study.

An experienced market watcher who has diabetes predicts the key to success will come down to one factor: ease of use.

The chief medical officer of Omada Health discusses a transition from one of the world's largest pharmaceutical companies to a digital health provider, and from treating chronic disease to preventing it.

Authors of the study say the technology exists to screen seniors with type 2 diabetes and identify those at risk of a fracture.

Truck drivers were identified in a Gallup survey as the profession most at risk for type 2 diabetes.

Experiments with baker's yeast showed why a fat-regulating enzyme is needed in the body.

Salt intake may be associated with an increased risk of developing diabetes. Research presented at the annual meeting of the European Association for the Study of Diabetes and published in Diabetologia found sodium intake increased the risk of developing both type 2 diabetes and latent autoimmune diabetes in adults.

While many payers, and the Blues in particular, have invested in digital health startups, a new agreement will pair Horizon with a company whose philosophy rejects the operating mentality of most insurers.

Screening for depression in the primary care setting can take as little as 30 seconds, but screening is only effective if it actually leads to intervention, explained Michael E. Thase, MD, professor of psychiatry and director of the Mood and Anxiety Program at the University of Pennsylvania.

Researchers noted that the oral therapy functions independently of insulin to carry excess blood glucose out of the system.

The results support policy positions that diabetes self-management education and support should occur at transitions in care.

The results were profound enough that researchers say it might be wise to screen patients for diabetes if their spouse is obese.

The problem caused an overdelivery of insulin in some cases. A design update in April 2017 corrected the problem but some patients still have lots of defective infusion sets.

How much does it cost for a drug maker to develop a new drug? Prior estimates have put this figure as high as $2.7 billion, but a new study indicates that the median cost of development for 10 cancer drugs was actually $648 million-a substantial discrepancy.

A group that represents both community-based and virtual providers finds many issues with CMS' proposal for Medicare's Diabetes Prevention Program.

As physicians treat patients with elevated low-density lipoprotein (LDL) cholesterol more aggressively with PCSK9 inhibitors and high-efficacy statins, a test that is more accurate at lower levels is essential.